Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Amgen clinical trials
The registry lists 1,085 studies whose lead sponsor is Amgen or one of 9 companies grouped under it. 51 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Amgen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Amgen.
- Amgen1,044 studiesSame company
Something wrong?
- Five Prime Therapeutics, Inc.11 studies →Acquired — became part of Amgen, Apr 16, 2021 · source ↗
Something wrong?
- 10 studies →
- 7 studies →
- 6 studies →
- 3 studies →
- 1 study →
- 1 study →
- Horizon Pharma Rheumatology LLC1 study →Acquired — became part of Amgen, Oct 6, 2023 · source ↗
Something wrong?
- Horizon Therapeutics Ireland DAC1 study →Acquired — became part of Amgen, Oct 6, 2023 · source ↗
Something wrong?
Focus areas
Conditions Amgen leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Arthritis, Rheumatoid59Neoplasms55Psoriasis53Renal Insufficiency, Chronic50Anemia48Multiple Myeloma42Hyperparathyroidism39Neoplasm Metastasis39Osteoporosis38Colorectal Neoplasms37Hyperparathyroidism, Secondary34Lung Neoplasms32Carcinoma, Non-Small-Cell Lung31Obesity30Hypercholesterolemia25Leukemia25Migraine Disorders24Lymphoma23Arthritis, Psoriatic22Prostatic Neoplasms22Osteoporosis, Postmenopausal21Thrombocytopenia20Bone Diseases, Metabolic19Breast Neoplasms19
Show all 46 areas
Kidney Failure, Chronic19Precursor Cell Lymphoblastic Leukemia-Lymphoma19Carcinoma18Hyperlipidemias18Lupus Erythematosus, Systemic18Melanoma18Purpura, Thrombocytopenic, Idiopathic18Small Cell Lung Carcinoma18Diabetes Mellitus, Type 216Lymphoma, Non-Hodgkin16Dermatitis, Atopic15Dyslipidemias15Stomach Neoplasms14Asthma13Renal Insufficiency13Graves Ophthalmopathy12Myelodysplastic Syndromes11Heart Failure10Neutropenia10Ovarian Neoplasms10Urea Cycle Disorders, Inborn10Vasculitis10
Studies
Recruiting first, then most recently updated. Showing 50 of 1,085. Browse all 1,085 →
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)RecruitingNCT06987539Phase 2
- A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Phase 3
- Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)RecruitingNCT07575399Phase 3
- Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisRecruitingNCT04804553Phase 3
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerRecruitingNCT07213674Phase 3
- AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid TumorsRecruitingNCT07403721Phase 1
- A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With Uncontrolled GoutRecruitingNCT07388498Phase 3
- A Trial of Inebilizumab in Participants With Autoimmune HepatitisRecruitingNCT07598825Phase 3
- A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular DegenerationRecruitingNCT07614776Phase 3
- Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC InjectionsRecruitingNCT07811999Phase 1
- Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or OverweightNot yet recruitingNCT07871409Phase 3
- Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityRecruitingNCT07037433Phase 3
- Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNot yet recruitingNCT07866066Phase 3
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune DiseasesRecruitingNCT06570798Phase 2
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)RecruitingNCT07684235Phase 3
- Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)RecruitingNCT07684144Phase 3
- A Phase 3 Study of Inebilizumab in Participants With Primary Membranous NephropathyRecruitingNCT07851220Phase 3
- A Study to Evaluate Avacopan in Participants With ANCA-associated VasculitisRecruitingNCT06072482Phase 4
- A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)RecruitingNCT07037758Phase 1
- Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)RecruitingNCT07297979Phase 1
- Comparing the Extent to Which Two Maridebart Cafraglutide Drug Products Are Made Available in the Body After a Single Subcutaneous DoseNot yet recruitingNCT07832799Phase 1
- A Trial Assessing the Effectiveness of Evolocumab in Reducing the Plaque Burden in Participants With Subclinical AtheromaNot yet recruitingNCT07803679Phase 4
- A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)RecruitingNCT07700238Phase 3
- Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)RecruitingNCT07778316Phase 3
- Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityRecruitingNCT07037459Phase 3
- A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic LeukaemiaNot yet recruitingNCT07223190Phase 3
- Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate CancerRecruitingNCT07493512Phase 1
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationRecruitingNCT06252649Phase 3
- Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During PregnancyRecruitingNCT05909761
- Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RDNot yet recruitingNCT07222553Phase 2
- A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese VolunteersRecruitingNCT07745907Phase 1
- A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving HemodialysisRecruitingNCT03969329Phase 3
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingNCT04221542Phase 1
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular EventsRecruitingNCT07136012Phase 3
- Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)RecruitingNCT07531095Phase 1
- A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes MellitusRecruitingNCT07590193Phase 1
- Evaluation of Neoadjuvant Xaluritamig in Localized Prostate CancerRecruitingNCT06613100Phase 1
- AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsRecruitingNCT07094113Phase 1
- Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's DiseaseRecruitingNCT04528082Phase 3
- An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye DiseaseRecruitingNCT07438405Phase 2
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationRecruitingNCT07172919Phase 2
- Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate CancerRecruitingNCT07140900Phase 1
- Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)RecruitingNCT06598306Phase 1
- Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis ImperfectaRecruitingNCT07366086Phase 3
- A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)RecruitingNCT06747949Phase 3
- Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography TrialRecruitingNCT07293260Phase 3
- A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisRecruitingNCT03633708Phase 3
- Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum DisorderRecruitingNCT05549258Phase 2
- A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisRecruitingNCT05767047Phase 3
- Aimovig Pregnancy Exposure RegistryRecruitingNCT06150781